PolyPid Welcomes New Chief Medical Officer, Dr. Tweezer-Zaks

PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

PolyPid Ltd. (NASDAQ: PYPD), a biopharmaceutical company dedicated to enhancing surgical outcomes, has recently announced a significant leadership change. Dr. Nurit Tweezer-Zaks has been appointed as the Chief Medical Officer, taking on this role as the company gears up for important regulatory submissions and product advancements. Dr. Tweezer-Zaks has been an invaluable member of PolyPid's Board of Directors since November 2023, and her transition into this executive position marks an exciting development for the firm.

"We are thrilled to welcome Dr. Tweezer-Zaks to our executive team at such a critical juncture for PolyPid, especially following our successful Phase 3 SHIELD II trial results," stated Dikla Czaczkes Akselbrad, PolyPid's CEO. With her comprehensive medical background and expertise in the industry, Dr. Tweezer-Zaks is well-prepared to drive the medical strategy forward during this transformative period. Her proven track record and insightful understanding of our technology will be essential as we approach our New Drug Application (NDA) submission and work to expand our pipeline.

Dr. Tweezer-Zaks' Expertise and Experience

Before joining PolyPid, Dr. Tweezer-Zaks served as the Chief Executive Officer of MediCane Health Inc., a global player in the medical cannabis sector. Her fascinating journey includes roles at aMOON Venture Capital Fund, where she held the position of Chief Medical Officer, contributing significantly to venture capital investments in life sciences. Furthermore, her time at Sanofi involved overseeing life cycle management for portfolio products and fostering external innovation, showcasing her exceptional range of expertise.

Dr. Tweezer-Zaks initiated her career as an internal medicine and rheumatology physician at the renowned Sheba Medical Center in Israel, where she practiced for nearly 15 years. This invaluable background in patient care enriches her understanding of the complexities involved in medical advancements.

Vision for the Future

Excited about this new role, Dr. Tweezer-Zaks expressed her enthusiasm by saying, "Joining the executive team is a remarkable opportunity, especially as we prepare for crucial regulatory submissions for our lead product, D-PLEX???, and further develop our promising pipeline, including our new GLP-1 program. The potential to address crucial unmet needs in surgical care, oncology, and metabolic diseases excites me immensely." Her commitment to innovation aligns perfectly with PolyPid's mission to provide groundbreaking solutions in healthcare.

Dr. Tweezer-Zaks holds both an M.D. and a B.S. from Ben-Gurion University School of Medicine and has earned an M.B.A. from the prestigious Kellogg-Recanati International Executive MBA Program, a unique collaboration between Northwestern University and Tel Aviv University.

About PolyPid

PolyPid Ltd. is at the forefront of biopharmaceutical innovation, focusing on enhancing surgical outcomes through locally administered therapeutics. Using their proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology, PolyPid combines active pharmaceutical ingredients for effective drug delivery over varied release periods, ranging from days to months. Following encouraging Phase 3 results for D-PLEX₁₀₀, which targets abdominal colorectal surgical site infections, the company anticipates submitting a New Drug Application in the near future. Furthermore, PolyPid boasts a robust pipeline with ongoing projects in oncology and diabetes management.

Frequently Asked Questions

Who is the new Chief Medical Officer of PolyPid?

Dr. Nurit Tweezer-Zaks has been appointed as the new Chief Medical Officer of PolyPid Ltd.

What are Dr. Tweezer-Zaks' qualifications?

Dr. Tweezer-Zaks holds M.D. and B.S. degrees from Ben-Gurion University and an M.B.A. from the Kellogg-Recanati International Executive MBA Program.

What is Dr. Tweezer-Zaks' prior experience?

She has served in significant leadership roles, including CEO of MediCane Health Inc. and Chief Medical Officer at aMOON Venture Capital Fund.

What products is PolyPid currently focused on?

PolyPid is focused on D-PLEX₁₀₀ for preventing surgical site infections and developing a pipeline addressing oncology and metabolic diseases.

What technology does PolyPid utilize?

PolyPid employs its proprietary PLEX technology for delivering therapeutics with controlled and extended-release capabilities.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.